Detalhe da pesquisa
1.
Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Br J Cancer
; 129(5): 782-790, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37443348
2.
Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity.
Immunology
; 166(1): 104-120, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35156714
3.
Immune characterization of metastatic colorectal cancer patients post reovirus administration.
BMC Cancer
; 20(1): 569, 2020 Jun 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32552875
4.
Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines.
Biochem Biophys Res Commun
; 517(2): 233-237, 2019 09 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31345575
5.
Importin-ß and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.
Ann Diagn Pathol
; 32: 28-34, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-29414394
6.
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Mol Ther
; 24(1): 166-74, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26310630
7.
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Mol Ther
; 23(5): 931-942, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25619724
8.
The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Invest New Drugs
; 33(3): 761-74, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25693885
9.
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
BMC Cancer
; 15: 513, 2015 Jul 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26156229
10.
Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.
Mol Ther
; 22(5): 1056-62, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24553100
11.
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Mol Ther
; 22(10): 1851-63, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24957982
12.
Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.
Appl Microbiol Biotechnol
; 98(4): 1763-70, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24419798
13.
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Cancer Immunol Res
; 12(3): 334-349, 2024 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38194598
14.
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.
Int J Cancer
; 132(10): 2327-38, 2013 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23114986
15.
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 696-706, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22886613
16.
Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
Invest New Drugs
; 31(6): 1476-86, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24121993
17.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Mol Ther
; 20(10): 1998-2003, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22871663
18.
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Clin Cancer Res
; 29(24): 5087-5103, 2023 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37812476
19.
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.
BMC Cancer
; 12: 368, 2012 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-22920673
20.
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.
Mol Ther
; 19(10): 1802-12, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21792179